Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from long-term extensions of the DURATION-1 and 3 studies evaluating BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the 71st Scientific Sessions of the American Diabetes Association.

Data from the DURATION-1 study showed that after three years, patients receiving BYDUREON experienced a significant reduction in A1C (1.6 percentage points), a measure of average blood sugar over three months, and weight (5.1 pounds) compared to baseline. (BYDUREON is not being studied as a weight-loss product.) BYDUREON-treated patients also experienced improvements from baseline in several cardiometabolic risk markers, including systolic blood pressure (-2.1 mmHg), total cholesterol (-9.9 mg/dL), LDL cholesterol (-7.0 mg/dL) and triglycerides (-12 percent).

Separately, results from the DURATION-3 study showed that at 84 weeks, patients treated with BYDUREON experienced significantly greater A1C reduction from baseline, sustained weight loss and a lower risk of hypoglycemia than patients treated with Lantus® (insulin glargine).  A1C reduction was 1.2 percentage points for BYDUREON compared with 1.0 percentage points for Lantus. Also, significantly more patients taking BYDUREON achieved an A1C of less than or equal to 6.5 percent. Patients on BYDUREON lost an average of 4.5 pounds while those on Lantus gained an average of 5.3 pounds, a difference of 9.8 pounds between the treatments.

"Faced with the progressive nature of type 2 d
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Aptuit LLC announces that Aptuit SSCI, ... , has enhanced its capabilities in the areas ... large molecules, including biologic drugs, metabolites, and polymers, ... mass spectrometer. In making the announcement, ... "The expanded large molecule capability enhances our early ...
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
Breaking Medicine Technology:Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... , FORT COLLINS, Colo., Dec. 14 Manchester Pharmaceuticals, ... (chenodiol tablets). On October 22, 2009, the US ... therapy for patients suffering from gallstones in whom surgery ... advanced age. , Chenodal prescriptions have started to be ...
... 14 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today ... the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. ... Associates, a federal health services consulting firm based in Falls ... nine members. , Dr. Blanck began his military career in ...
Cached Medicine Technology:Manchester Announces Availability of Chenodal(TM) 2Oxygen Biotherapeutics, Inc. Expands Board of Directors 2
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut Pro ... Vol.3, a customizable title tool for FCPX , ... dragging ProIntro Vol.3 in their timeline" says Christina Austin, CEO ... saver and i think our users will agree" , ProIntro ... made with Final Cut Pro X users in mind. Achieve ...
(Date:8/23/2014)... 23, 2014 Youth substance abuse is ... no different in Houston, TX. Substance abuse can happen ... to drug and alcohol dependency in higher numbers than ... beat substance abuse, but don’t know where to find ... can be a challenge because most treatment options are ...
(Date:8/23/2014)... 2014 Summer vacation is almost over and ... in session. While shopping for school supplies and a new ... encourages parents and students to also spend some time brushing ... excellent hitchhikers and thrive in heavily populated places,” said Randy ... and dorms the perfect settings for bed bugs to take ...
(Date:8/22/2014)... August 23, 2014 2014 Deep ... a professional and in-depth research report on the ... Meter information, including Glucose Meter definition, classification, application, ... overview. This research covers the international market analysis, ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online Health ... Plans. , According to Zane Benefits, employers are adopting ... the cost of healthcare without reducing coverage for employees. ... can be confusing. , The new guide contains a ... types of ABHPs. It also explains the similarities, ...
Breaking Medicine News(10 mins):Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:Expert Advice for a Bed Bug-Free School Year 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3
... News) -- "Team-based care" should be used to improve ... Community Preventive Services recommended on Tuesday. The recommendation ... showed improvements in patients, control of blood pressure when ... -- a primary care doctor supported by a pharmacist, ...
... who undergo one of the most common treatments for ... according to new research by Henry Ford Hospital. ... level of the surgeon doing the procedure mattered somewhat ... on data gathered throughout the U.S., will be presented ...
... Rice University freshmen took a mousetrap and built a better ... "The goal was to regulate the amount of fluid ... said Melissa Yuan, a member of the IV DRIP (Dehydrated ... designed to be used in severely underdeveloped parts of the ...
... HealthDay Reporter , TUESDAY, May 15 (HealthDay News) ... arteries, it may not be useful to give them ... symptoms such as chest pain or shortness of breath, ... populations of post-angioplasty and post-bypass patients; screening asymptomatic patients ...
... 15, 2012) - Beta-carotene, selenium and folic acid taken ... are probably harmless. But taken at much higher levels as ... proven to increase the risk of developing a host of ... they,re essential and we need them, but we need them ...
... recent research released in June,s Journal of Thoracic Oncology ... the lungs might be an additional predictive technique for lung ... found that 96.4 percent of the positive CT screening results ... more accurately diagnose patients. This research focused on a way ...
Cached Medicine News:Health News:U.S. Task Force Issues Blood Pressure Guidelines 2Health News:Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery 2Health News:This 'mousetrap' may save lives 2Health News:Are Post-Angioplasty Stress Tests Unnecessary? 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: